LRMR — Larimar Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374690 ·
Last close
$2.67
Market Cap
$277.37M
52W High
$6.42
52W Low
$2.61
ADV30
1,231,880
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -34,351,000 | -32,782,000 | 165,302,000 | 92,687,000 | 37,920,000 |
| Mar 2026 | 0 | — | -31,117,000 | -29,613,000 | 208,511,000 | 177,913,000 | 50,478,000 |
| Dec 2025 | 0 | — | -64,018,000 | -62,498,000 | 145,842,000 | 85,412,000 | 67,757,000 |
| Sep 2025 | 0 | — | -49,499,000 | -47,712,000 | 187,350,000 | 90,140,000 | 48,312,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-155,924,000
Investing CF
$55,108,000
Financing CF
$172,766,000
CapEx
$-270,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.95
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-497,226,000
Inventory
—
Receivables
$267,000
ST Investments
$63,580,000
EBIT TTM
$-178,985,000
Pretax Income TTM
$-172,605,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,497,000 | -165,673,000 | 145,842,000 | 67,757,000 | 78,085,000 | -113,201,000 |
| Dec 2024 | 0 | -90,890,000 | -80,604,000 | 200,225,000 | 28,413,000 | 171,812,000 | -70,760,000 |
| Dec 2023 | 0 | -41,758,000 | -36,949,000 | 95,935,000 | 14,215,000 | 81,720,000 | -33,459,000 |
| Dec 2022 | 0 | -36,526,000 | -35,355,000 | 126,405,000 | 15,502,000 | 110,903,000 | -27,569,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-166,005,000
OpCashFlow TTM
—
Assets (Latest)
$208,511,000
Forward EPS
$-1.06
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.67 · call volume: 87 · put volume: 45
Expected Move to 2026-12-18:
±$2.38
(88.95%) —
implied range
$0.30 –
$5.05
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $276.39M | $0.20 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $276.31M | $4.57 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $274.78M | $0.26 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $281.02M | $2.56 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $282.49M | $4.94 | — |
News headlines (Yahoo Finance, 1h cache)
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-05 12:35 · Yahoo
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
2026-09-29 20:05 · Yahoo
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
2026-07-15 15:43 · Yahoo
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
2026-07-08 22:44 · Yahoo
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
2026-07-03 13:13 · Yahoo
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
2026-07-02 20:32 · Yahoo
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
2026-06-29 14:00 · Yahoo
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
2026-06-29 13:02 · Yahoo
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp
2026-06-29 12:26 · Yahoo
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
2026-06-29 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.